PTC Therapeutics (PTCT) News Today

Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 113,500 shares of the biopharmaceutical company's stock, valued at

Seven Eight Capital LP grew its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 148.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,692 shares of the biopharmaceutical company's stock after p

Edgestream Partners L.P. boosted its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 49.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,522 shares of the biopharmaceutical company's

Russell Investments Group Ltd. increased its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 57.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 301,790 shares of th

BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 8.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 439,365 shares of t

Empowered Funds LLC bought a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 41,598 shares of the biopharmaceutic

Susquehanna Portfolio Strategies LLC cut its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 62.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 29,900 shares of the biopharmaceutical company's stock after selling 50,57

PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) saw a significant drop in short interest in the month of June. As of June 30th, there was short interest totalling 5,600,000 shares, a drop of 23.8% from the June 15th total of 7,350,000 shares. Based on an average daily trading volume, of 967,000 shares, the days-to-cover ratio is currently 5.8 days.

Morgan Stanley increased their price target on shares of PTC Therapeutics from $30.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Friday.

BNP Paribas Financial Markets cut its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 46.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 199,670 shares of the biopharmaceutical company's stock after selling 171,

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) have been assigned a consensus rating of "Hold" from the fourteen analysts that are presently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating

Vanguard Group Inc. boosted its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 10.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,800,843 shares of the biopharmaceutical company's stock after acquiring an add

PTC Therapeutics (NASDAQ:PTCT) Shares Gap Down to $34.66

PTC Therapeutics (NASDAQ:PTCT) Trading Up 8.2% on Analyst Upgrade

Bank of America increased their target price on PTC Therapeutics from $25.00 to $32.00 and gave the stock an "underperform" rating in a research report on Friday.

JPMorgan Chase & Co. reaffirmed an "overweight" rating and issued a $53.00 target price on shares of PTC Therapeutics in a report on Thursday.

PTC Therapeutics (NASDAQ:PTCT) Stock Price Down 6.8%

Wellington Management Group LLP boosted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 4.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,816,603 shares of the biopharmaceutical company's stock

PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) was the target of a significant decline in short interest in May. As of May 31st, there was short interest totalling 7,490,000 shares, a decline of 16.0% from the May 15th total of 8,920,000 shares. Based on an average daily trading volume, of 880,100 shares, the days-to-cover ratio is currently 8.5 days.

Seven Eight Capital LP decreased its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 63.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,637 shares of the biopha

RTW Investments LP raised its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 2.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,423,970 shares of the biopharmaceutical company's stock after buying

Armistice Capital LLC grew its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 11.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,864,000 shares of the biopharmaceutical company's stock aft

Norges Bank bought a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 546,375 shares of the biopharmaceutical company's stock, valued at approximately

The Goldman Sachs Group lifted their price objective on shares of PTC Therapeutics from $18.00 to $32.00 and gave the company a "sell" rating in a report on Tuesday.

Trexquant Investment LP purchased a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 232,663 shares of the biopharmaceutical company's stock, valued at approximately $6,412,000